```
=> d his

     (FILE 'HOME' ENTERED AT 06:46:48 ON 01 OCT 2007)

     FILE 'REGISTRY' ENTERED AT 06:46:55 ON 01 OCT 2007
L1       1776331 S NC4/ESS (S) C6/ESS
L2         37784 S NOC3/ESS (S) C6/ESS
L3               STRUCTURE UPLOADED
L4          2143 S L1 AND L2
L5            10 S L3 SAM SUB=L4
L6           117 S L3 SSS FULL SUB=L4

     FILE 'CAPLUS' ENTERED AT 06:48:09 ON 01 OCT 2007
L7             6 S L6
L8             1 S US200!-525470/APPS
L9             5 S L7 NOT L8

     FILE 'REGISTRY' ENTERED AT 06:48:32 ON 01 OCT 2007

=> d l3
L3 HAS NO ANSWERS
L3                STR
```



Structure attributes must be viewed using STN Express query preparation.

C:\Program Files\Stnexp\Queries\10525470-broad-F.str





chain nodes :
8 9 10 11
ring nodes :
1 2 3 4 5 6
chain bonds :
1-11 8-10 8-9 8-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-11 8-10 8-9 8-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:203619 CAPLUS
DN 140:253441
TI Preparation of indoles having aryloxyalkanoic or arylalkanoic acid substituents as PPARγ agonists or partial agonists having anti-diabetic activity
IN Acton, John J., III; Meinke, Peter T.; Wood, Harold B.; Black, Regina M.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004019869	A2	20040311	WO 2003-US26679	20030828
	WO 2004019869	A3	20040624		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2495915	A1	20040311	CA 2003-2495915	20030828
	AU 2003260085	A1	20040319	AU 2003-260085	20030828
	EP 1546142	A2	20050629	EP 2003-791782	20030828
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006500382	T	20060105	JP 2004-531472	20030828
	US 2005272788	A1	20051208	US 2005-525470	20050224 <--
PRAI	US 2002-406737P	P	20020829		
	US 2003-440741P	P	20030117		
	WO 2003-US26679	W	20030828		

OS MARPAT 140:253441
GI



I



II



III

AB Indoles having aryloxyalkanoic acid substituents or arylalkanoic acid substituents are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes. Indoles having aryloxyalkanoic acid or arylalkanoic acid substituents (shown as I; variables defined below; e.g. III) are agonists or partial agonists of PPARγ and are useful in the treatment and control of hyperglycemia that is symptomatic of type 2 diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes. Compds. I have EC50 = 1-3000 nM in Gal-4 hPPAR transactivation assays (no data for individual compds. are given). For I: R1 is II wherein X = a bond, O, S(O)n, CO, CH2, CHMe, CMe2, and C3-6cycloalkylidene; Y = -CH:CH-, -CH(OH)CH(OH)-, -OCR7R8-, -SCR7R8-, and -CH2CR5R6-; Z = -CO2H and tetrazole; A = H, C1-4 alkyl, C1-4 alkenyl, -O1-4-alkyl, and halogen, wherein alkyl, alkenyl, and Oalkyl are (un)substituted with 1-5 halogens. R5, R6, R7, and R8 = H, halogen, C1-C5 alkyl, OC1-C5 alkyl, C2-C5 alkenyl, OC2-C5 alkenyl, C3-6 cycloalkyl, (CH2)0-2phenyl, -O(CH2)0-2phenyl and CO2H, wherein C1-C5 alkyl, OC1-C5 alkyl, C2-C5 alkenyl, OC2-C5 alkenyl, C3-6 cycloalkyl, and Ph are (un)substituted with 1-5 halogens, and C3-6 cycloalkyl and Ph are further (un)substituted with 1-3 C1-C3 alkyl and OC1-C3 alkyl, said C1-C3 alkyl and OC1-C3 alkyl being (un)substituted with 1-3 halogens; or R7 and R8 may be connected to form a C3-C6 cycloalkyl group, said C3-C6 cycloalkyl being (un)substituted with 1-3 halogens; or, when Y is OCR7R8, R8 may optionally be a 1-2-C bridge connected to the Ph ring at the position ortho to Y, thereby yielding a 5 or 6-membered heterocyclic ring fused to the Ph ring. R2 is C1-C4 alkyl, which is (un)substituted with 1-5 halogens; R3 = 3-benzisoxazolyl, 3-benzisothiazolyl, and 3-benzpyrazolyl, wherein R3 is (un)substituted with 1-3 halogen, C1-3alkyl, and OC1-3alkyl, wherein C1-3alkyl and OC1-3alkyl are (un)substituted with 1-5 halogens; each R4 = halogen, C1-C3 alkyl, and OC1-C5 alkyl, wherein C1-C3 alkyl and OC1-C5 alkyl are (un)substituted with 1-5 halogens; n = 0-2; p = 0-3; and q = 0-3. Although the methods of preparation are not claimed, 11 example prepns. are included. For example, III was prepared in 8 steps starting with substitution of chloroacetone with 3-benzoyloxyphenol to give 1-(3-hydroxyphenoxy)-2-propanone followed by cyclization with 4-trifluoromethoxyphenylhydrazine hydrochloride to give 3-(3-hydroxyphenoxy)-2-methyl-5-(trifluoromethoxy)-1H-indole, followed by O-protection, followed by substitution at N with 3,6-dichloro-1,2-benzisoxazole, followed by deprotection at O, followed by etherification with iso-Bu (R)-lactate, followed by base hydrolysis of the ester functionality, followed by substitution of MeO for Cl.

=> d l9 tot bib abs hitstr

L9 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:120163 CAPLUS Full-text
DN 144:212651
TI Indoles as PPARγ agonists, their preparation, pharmaceutical compositions, and use in therapy
IN Liu, Kun; Meinke, Peter T.; Wood, Harold B.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006014262	A2	20060209	WO 2005-US22906	20050628
WO 2006014262	A3	20060803		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005270201	A1	20060209	AU 2005-270201	20050628
CA 2571789	A1	20060209	CA 2005-2571789	20050628
EP 1765329	A2	20070328	EP 2005-763114	20050628
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV				
CN 1980659	A	20070613	CN 2005-80022610	20050628
IN 2006DN08006	A	20070803	IN 2006-DN8006	20061229
PRAI US 2004-585046P	P	20040702		
WO 2005-US22906	W	20050628		

OS MARPAT 144:212651
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to indoles of formula I, which are peroxisome proliferator-activated receptor (PPAR) gamma agonists or partial agonists. In compds. I, each R1 is independently selected from H, halo, C1-3 alkyl, and C1-3 alkoxy, where the alkyl and alkoxy are optionally substituted with 1-5 halogens; R2 is C1-4 alkyl, optionally substituted with 1-5 halogens; R3 is selected from (un)substituted benzisoxazolyl, (un)substituted aryl, (un)substituted aroyl, (un)substituted aryloxy, and (un)substituted aryl-S(O)n-, where n is 0-2; X and Y are independently selected from a bond and (un)substituted methylene; Z is dioxothiazolidinyl or dioxooxazolidinyl; Ar is Ph, naphthyl, or heteroaryl; and p is 0-3. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I and a

pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment and control of type 2 diabetes mellitus and associated conditions, such as obesity and lipid disorders. Substitution of chloroacetone with 4-chlorophenol followed by condensation with 3-(trifluoromethoxy)phenylhydrazine and cyclization gave indole II. Heterocyclization of glycolamide with di-Et carbonate followed by N-protection, deprotonation and substitution of 1,3- bis(bromomethyl)benzene resulted in the formation of oxazolidinedione III, which was substituted with indole II and deprotected to give IV. The compds. of the invention are agonists of PPAR, expressing EC50 values between 1 nM and 3.0 μM.

IT 875542-37-3P 875542-38-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of indoles as PPARγ agonists useful as antidiabetics)

RN 875542-37-3 CAPLUS
CN 2,4-Oxazolidinedione, 5-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenyl]-5-methyl-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 875542-38-4 CAPLUS
CN 2,4-Oxazolidinedione, 5-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenyl]-5-methyl-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 668455-75-2P, 6-Methoxy-3-[2-methyl-1-[(4-methylphenyl)sulfonyl]-6-(trifluoromethoxy)-1H-indol-3-yl]-1,2-benzisoxazole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indoles as PPARγ agonists useful as antidiabetics)

RN 668455-75-2 CAPLUS
CN 1H-Indole, 3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-1-[(4-methylphenyl)sulfonyl]-6-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



L9 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:378862 CAPLUS Full-text
DN 143:78030
TI Selective PPARγ modulators with improved pharmacological profiles
AU Liu, Kun; Black, Regina M.; Acton, John J.; Mosley, Ralph; Debenham, Sheryl; Abola, Ramon; Yang, Meng; Tschirret-Guth, Richard; Colwell, Lawrence; Liu, Cherrie; Wu, Margaret; Wang, Chuanlin F.; MacNaul, Karen L.; McCann, Margaret E.; Moller, David E.; Berger, Joel P.; Meinke, Peter T.; Jones, A. Brian; Wood, Harold B.
CS Merck Research Laboratories, Rahway, NJ, 07065, USA
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(10), 2437-2440
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 143:78030
AB A series of metabolically robust N-benzyl indole-selective PPARγ modulators with either a 3-benzoyl or 3-benzisoxazoyl moiety have been identified. In vitro, these compds. are partial agonists and exhibit reduced adipogenesis in human adipocytes. In vivo, these SPPARγMs (selective modulators) result in potent glucose lowering in db/db mice and attenuate increases in heart weight and brown adipose tissue that is typically observed in rats upon treatment with PPARγ full agonists.
IT 668489-67-6P 668489-97-2P 668490-04-8P
668490-08-2P 854933-09-8P 854933-10-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of (S)-[chloro[[(benzisoxazolyl)(trifluoromethoxy)indolyl]oxy]phenoxy]propanoic acid and study of its activity as partial agonist toward PPARγ)

RN 668489-67-6 CAPLUS
CN Propanoic acid, 2-[3-[[1-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-5-

(trifluoromethoxy)-1H-indol-3-yl]oxy]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668489-97-2 CAPLUS
CN Propanoic acid, 2-[4-chloro-3-[[1-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-5-(trifluoromethoxy)-1H-indol-3-yl]oxy]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668490-04-8 CAPLUS
CN Propanoic acid, 2-[2-chloro-5-[[1-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-5-(trifluoromethoxy)-1H-indol-3-yl]oxy]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668490-08-2 CAPLUS
CN Propanoic acid, 2-[3-chloro-5-[[1-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-5-(trifluoromethoxy)-1H-indol-3-yl]oxy]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 854933-09-8 CAPLUS
CN Propanoic acid, 2-[3-[[1-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-5-(trifluoromethoxy)-1H-indol-3-yl]oxy]-2-propylphenoxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 854933-10-1 CAPLUS
CN Propanoic acid, 2-[5-[[1-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-5-(trifluoromethoxy)-1H-indol-3-yl]oxy]-2-propylphenoxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 668455-69-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of (S)-[methoxy[[(benzisoxazolyl)(trifluoromethoxy)indolyl]oxy]phenoxy]propanoic acid, study of its activity as partial agonist toward PPARγ, effect on human adipocytes, and dose-dependent glucose lowering)
RN 668455-69-4 CAPLUS
CN Propanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:948905 CAPLUS Full-text
DN 142:385959
TI Gene expression profiles for determining whether an agent possesses a defined biological activity using efficacy, toxicity, and classifier comparisons
IN Lum, Pek Yee; Tan, Yejun; Dai, Hongyue; Muise, Eric Stanley; Berger, Joel P.; Thompson, John R.
PA USA
SO U.S. Pat. Appl. Publ., 51 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005084872	A1	20050421	US 2004-764420	20040123
PRAI US 2003-442797P	P	20030124		
US 2003-474413P	P	20030530		

AB In one aspect, the present invention provides methods for determining whether an agent (e.g., candidate drug) possesses a biol. activity and populations of nucleic acid mols. useful as probes for measuring the level of expression of populations of genes. The methods comprise includes 3 steps. Efficacy values of the agents are compared to at least one reference efficacy value to shield an efficacy comparison result, wherein each efficacy value represents at least one expression pattern of the same efficacy-related population of genes, or at least one expression pattern of the same efficacy-related population of proteins. Toxicity values of the agent are compared to at least one reference toxicity value to yield a toxicity comparison result based on gene expression in an analogous fashion. Third, a classifier value of the agent is compared to at least one reference classifier value to yield a classifier comparison value. The comparison result(s) obtained from efficacy, toxicity, and classifier values determine whether the agent possesses the defined biol. activity. The method is exemplified by identified gene expression patterns for agonists, or partial agonists, of peroxisome proliferator-activator receptor γ (PPARγ) in mouse and rat models.
IT 668455-69-4, Page 34 849794-15-6, Page 34
RL: ADV (Adverse effect, including toxicity); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reference agent; gene expression profiles for determining whether agent possesses
defined biol. activity using efficacy, toxicity, and classifier

comparisons)
RN 668455-69-4 CAPLUS
CN Propanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849794-15-6 CAPLUS
CN Propanoic acid, 2-[4-chloro-3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]oxy]phenoxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:203803 CAPLUS Full-text
DN 140:253443
TI Preparation of indoles having aryloxyalkanoic or arylalkanoic acid substituents as PPARγ agonists or partial agonists having anti-diabetic activity
IN Acton, John J., III; Debenham, Sheryl D.; Liu, Kun; Meinke, Peter T.; Wood, Harold B.; Black, Regina M.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 190 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004020409	A1	20040311	WO 2003-US27156	20030827
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2495943	A1	20040311	CA 2003-2495943	20030827
	AU 2003262984	A1	20040319	AU 2003-262984	20030827
	EP 1537078	A1	20050608	EP 2003-791952	20030827
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1678578	A	20051005	CN 2003-820691	20030827
	JP 2006500384	T	20060105	JP 2004-531948	20030827
	US 2005277685	A1	20051215	US 2005-524697	20050216
	US 7186746	B2	20070306		
	US 2007161689	A1	20070712	US 2007-714341	20070306
PRAI	US 2002-406741P	P	20020829		
	US 2003-440672P	P	20030117		
	WO 2003-US27156	W	20030827		
	US 2005-524697	A3	20050216		

OS MARPAT 140:253443

GI



I

II

AB Indoles having aryloxyalkanoic acid or arylalkanoic acid substituents (shown as I; variables defined below; e.g. II) are agonists or partial agonists of PPARγ and are useful in the treatment and control of hyperglycemia that is symptomatic of type 2 diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes. For I: R1 = -X-Aryl-Y-Z, and -X-Heteroaryl-Y-Z, wherein Aryl and Heteroaryl are (un)substituted with 1-3 A; Aryl is Ph or naphthyl; Heteroaryl is a monocyclic or fused bicyclic aromatic ring structure containing 1-4 heteroatoms = N, O, and S(O)n, wherein the monocyclic ring or each ring of the bicyclic ring structure is a 5-6 membered ring; X = a bond, CH2, CHMe, CMe2, and C3-C6cycloalkylidene; Y = -CH:CH-, -CH(OH)CH(OH)-, -OCR7R8-, -SCR7R8-, and -CH2CR5R6-; Z = -CO2H and tetrazole; A = C1-4 alkyl, C1-4 alkenyl, -OC1-4 alkyl, and halogen, wherein alkyl, alkenyl, and -Oalkyl are each (un)substituted with 1-5 halogens. R2 is C1-C4 alkyl, which is (un)substituted with 1-5 halogens; R3 = benzisoxazolyl, benzisothiazolyl, benzopyrazolyl, Aryl, -C(O)Aryl, -C(O)Heteroaryl, -OAryl, OHeteroaryl, -S(O)nAryl, and -S(O)nHeteroaryl, wherein R3 is (un)substituted with 1-3 halogen, C1-3alkyl, -OC1-3alkyl, and -SC1-3 alkyl, wherein C1-3alkyl, -OC1-3alkyl, and-SC1-3alkyl are (un)substituted with 1-5 halogens; each R4 is optionally = H, halogen, C1-C5 alkyl and -OC1-C5 alkyl, wherein C1-C5 alkyl and -OC1-C5 alkyl are (un)substituted with 1-5 halogens; n = 0-2; and p = 1-3; addnl. details are given in the claims. Compds. I have EC50 = 1-3000 nM in Gal-4 hPPAR transactivation assays (no data for individual compds. are given). Although the methods of preparation are not claimed, 32 example prepns. are included. For example, II was prepared in 5 steps starting with N-arylation of 2-methyl-6-trifluoromethoxyindole by 3-bromoanisole to give 1-(3-methoxyphenyl)-2-methyl-6- trifluoromethoxyindole, followed by ether cleavage, followed by substitution at the 3-position with 4-methoxybenzoyl chloride, followed by ether formation with (S)-Et lactate and finally base hydrolysis of the ester functionality.

IT 668455-69-4P, (2R)-2-[4-Chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-50-6P, (2S)-2-[3-[[3-(6-Methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-51-7P, (2S)-2-[3-[[3-(6-Chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-52-8P, (2R)-2-[3-[[3-(6-Chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-53-9P, (2R)-2-[3-[[3-(6-Methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-54-0P, (2S)-2-[3-[[3-(7-Methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-55-1P, (2R)-2-[3-[[3-(7-Methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-56-2P, (2R)-2-[2-Chloro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-57-3P, (2S)-2-[2-Chloro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-62-0P, (2S)-2-[3-[[3-(6-Methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]butanoic acid 668456-64-2P, (2R)-2-[3-[[3-(6-Methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]butanoic acid 668456-65-3P, (2R)-2-[3-[[3-(6-Methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-3-methylbutanoic acid 668456-66-4P, (2S)-2-[4-Chloro-3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-67-5P, (2S)-2-[2-Chloro-5-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-68-6P, (2R)-2-[4-Chloro-3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-69-7P, (2S)-2-[3-[[3-(6-Chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]butanoic acid 668456-70-0P, (2R)-2-[3-[[3-(6-Chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]butanoic acid 668456-71-1P, (2S)-2-[4-Chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-72-2P, (2S)-2-[3-[[3-(5-Methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-

(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-73-3P, (2R)-2-[3-[[3-(5-Methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-74-4P, (2R)-2-[4-Chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]butanoic acid 668456-75-5P, (2S)-2-[4-Chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]butanoic acid 669456-76-6P, 2-[3-[[3-(6-Methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]pentanoic acid 668456-77-7P, (2S)-2-[3-[[3-(6-Methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-3-methylbutanoic acid 668456-78-8P, (2R)-2-[2-Chloro-5-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-79-9P, (2S)-2-[4-Chloro-3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]butanoic acid 668456-80-2P, (2R)-2-[4-Chloro-3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]butanoic acid 668456-81-3P, (2S)-2-[5-[[3-(6-Chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]-2-fluorophenoxy]propanoic acid 668456-82-4P, (2R)-2-[5-[[3-(6-Chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]-2-fluorophenoxy]propanoic acid 668456-83-5P, (2S)-2-[3-[[3-(6-Chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]-4-fluorophenoxy]propanoic acid 668456-84-6P, (2R)-2-[3-[[3-(6-Chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]-4-fluorophenoxy]propanoic acid 668456-85-7P, (2S)-2-[2-Fluoro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-86-8P, (2R)-2-[2-Fluoro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-87-9P, 2-[4-Chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-2-methylpropanoic acid 668456-88-0P, (2S)-2-[4-Fluoro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-89-1P, (2R)-2-[4-Fluoro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid 668456-90-4P, 2-[2-Chloro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]pentanoic acid 668456-91-5P, 2-[4-Chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]pentanoic acid 668456-92-6P, 2-[4-Chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-3-methylbutanoic acid 668458-59-1P, (2S)-2-[3-[[3-(6-Methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid sodium salt 668458-60-4P, (2S)-2-[3-[[3-(6-Chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid sodium salt 668458-61-5P, (2R)-2-[3-[[3-(6-Chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid sodium salt 668458-62-6P, (2R)-2-[3-[[3-(6-Methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid sodium salt 668458-63-7P, (2S)-2-[3-[[3-(7-Methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid sodium salt 668458-64-8P, (2R)-2-[3-[[3-(7-Methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid

sodium salt 668458-65-9P, (2R)-2-[2-Chloro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid sodium salt 668458-66-0P, (2R)-2-[4-Chloro-3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid sodium salt 668458-67-1P, (2S)-2-[2-Chloro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoic acid sodium salt

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of indoles having aryloxyalkanoic or arylalkanoic acid substituents as PPARγ agonists or partial agonists having anti-diabetic activity)

RN 668455-69-4 CAPLUS

CN Propanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-50-6 CAPLUS

CN Propanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-51-7 CAPLUS

CN Propanoic acid, 2-[3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-

(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-52-8 CAPLUS
CN Propanoic acid, 2-[3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-53-9 CAPLUS
CN Propanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-54-0 CAPLUS
CN Propanoic acid, 2-[3-[[3-(7-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-55-1 CAPLUS
CN Propanoic acid, 2-[3-[[3-(7-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-56-2 CAPLUS
CN Propanoic acid, 2-[2-chloro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-57-3 CAPLUS
CN Propanoic acid, 2-[2-chloro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-62-0 CAPLUS
CN Butanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-64-2 CAPLUS
CN Butanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-65-3 CAPLUS
CN Butanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-66-4 CAPLUS
CN Propanoic acid, 2-[4-chloro-3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-

methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-67-5 CAPLUS
CN Propanoic acid, 2-[2-chloro-5-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-68-6 CAPLUS
CN Propanoic acid, 2-[4-chloro-3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-69-7 CAPLUS
CN Butanoic acid, 2-[3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-70-0 CAPLUS
CN Butanoic acid, 2-[3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-71-1 CAPLUS
CN Propanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-

methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-72-2 CAPLUS
CN Propanoic acid, 2-[3-[[3-(5-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-73-3 CAPLUS
CN Propanoic acid, 2-[3-[[3-(5-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-74-4 CAPLUS
CN Butanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-75-5 CAPLUS
CN Butanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-76-6 CAPLUS
CN Pentanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 668456-77-7 CAPLUS
CN Butanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-78-8 CAPLUS
CN Propanoic acid, 2-[2-chloro-5-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-79-9 CAPLUS
CN Butanoic acid, 2-[4-chloro-3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-80-2 CAPLUS
CN Butanoic acid, 2-[4-chloro-3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-81-3 CAPLUS
CN Propanoic acid, 2-[5-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]-2-fluorophenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-82-4 CAPLUS
CN Propanoic acid, 2-[5-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]-2-fluorophenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-83-5 CAPLUS
CN Propanoic acid, 2-[3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]-4-fluorophenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-84-6 CAPLUS
CN Propanoic acid, 2-[3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]-4-fluorophenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-85-7 CAPLUS
CN Propanoic acid, 2-[2-fluoro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-86-8 CAPLUS
CN Propanoic acid, 2-[2-fluoro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-87-9 CAPLUS
CN Propanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 668456-88-0 CAPLUS
CN Propanoic acid, 2-[4-fluoro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-89-1 CAPLUS
CN Propanoic acid, 2-[4-fluoro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-90-4 CAPLUS
CN Pentanoic acid, 2-[2-chloro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 668456-91-5 CAPLUS
CN Pentanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 668456-92-6 CAPLUS
CN Butanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-3-methyl- (9CI) (CA INDEX NAME)



RN 668458-59-1 CAPLUS
CN Propanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 668458-60-4 CAPLUS

CN Propanoic acid, 2-[3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 668458-61-5 CAPLUS
CN Propanoic acid, 2-[3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 668458-62-6 CAPLUS
CN Propanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668458-63-7 CAPLUS
CN Propanoic acid, 2-[3-[[3-(7-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668458-64-8 CAPLUS
CN Propanoic acid, 2-[3-[[3-(7-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668458-65-9 CAPLUS
CN Propanoic acid, 2-[2-chloro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668458-66-0 CAPLUS
CN Propanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668458-67-1 CAPLUS
CN Propanoic acid, 2-[2-chloro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 668455-75-2P, 6-Methoxy-3-[2-methyl-1-[(4-methylphenyl)sulfonyl]-6-(trifluoromethoxy)-1H-indol-3-yl]-1,2-benzisoxazole 668455-77-4P , Methyl (2R)-2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]propanoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indoles having aryloxyalkanoic or arylalkanoic acid substituents as PPARγ agonists or partial agonists having anti-diabetic activity)

RN 668455-75-2 CAPLUS
CN 1H-Indole, 3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-1-[(4-methylphenyl)sulfonyl]-6-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 668455-77-4 CAPLUS
CN Propanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L[illegible] ANSWER [illegible] OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:203808 CAPLUS Full-text
DN 140:253442
TI Preparation of indoles having aryloxyalkanoic or arylalkanoic acid substituents as PPARγ agonists or partial agonists having anti-diabetic activity
IN Acton, John J., III; Debenham, Sheryl D.; Liu, Kun; Meinke, Peter T.; Wood, Harold B.; Black, Regina M.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 184 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004020408	A1	20040311	WO 2003-US26677	20030827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,				

PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003265681	A1	20040319	AU 2003-265681		20030827
BR 2003013825	A	20050712	BR 2003-13825		20030827
CN 1678578	A	20051005	CN 2003-820691		20030827
IN 2005CN00257	A	20070525	IN 2005-CN257		20050224
MX 2005PA02303	A	20050608	MX 2005-PA2303		20050225
NO 2005001546	A	20050524	NO 2005-1546		20050323
PRAI US 2002-406741P	P	20020829			
US 2003-440672P	P	20030117			
WO 2003-US26677	W	20030827			

OS MARPAT 140:253442
GI



II

AB Indoles having aryloxyalkanoic acid or arylalkanoic acid substituents (shown as I; variables defined below; e.g. II) are agonists or partial agonists of PPARγ and are useful in the treatment and control of hyperglycemia that is symptomatic of type 2 diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes. For I: R1 = -X-Aryl-Y-Z, and -X-Heteroaryl-Y-Z, wherein Aryl and Heteroaryl are (un)substituted with 1-3 A; Aryl is Ph or naphthyl; Heteroaryl is a monocyclic or fused bicyclic aromatic ring structure containing 1-4 heteroatoms = N, O, and S(O)n, wherein the monocyclic ring or each ring of the bicyclic ring structure is a 5-6 membered ring; X = a bond, CH2, CHMe, CMe2, and C3-C6cycloalkylidene; Y = -CH:CH-, -CH(OH)CH(OH)-, -OCR7R8-, -SCR7R8-, and -CH2CR5R6-; Z = -CO2H and tetrazole; A = C1-4 alkyl, C1-4 alkenyl, -OC1-4 alkyl, and halogen, wherein alkyl, alkenyl, and -Oalkyl are each (un)substituted with 1-5 halogens. R2 is C1-C4 alkyl, which is (un)substituted with 1-5 halogens; R3 = benzisoxazolyl, benzisothiazolyl, benzopyrazolyl, Aryl, -C(O)Aryl, -C(O)Heteroaryl, -OAryl, OHeteroaryl, -S(O)nAryl, and -S(O)nHeteroaryl, wherein R3 is (un)substituted with 1-3 halogen, C1-3alkyl, -OC1-3alkyl, and -SC1-3 alkyl, wherein C1-3alkyl, -OC1-3alkyl, and-SC1-3alkyl are (un)substituted with 1-5 halogens; each R4 is optionally = H, halogen, C1-C5 alkyl and -OC1-C5 alkyl, wherein C1-C5 alkyl and -OC1-C5 alkyl are (un)substituted with 1-5 halogens; n = 0-2; and p = 1-3; addnl. details are given in the claims. Compds. I have EC50 = 1-3000 nM in

Gal-4 hPPAR transactivation assays (no data for individual compds. are given). Although the methods of preparation are not claimed, 32 example prepns. are included. For example, II was prepared in 5 steps starting with N-arylation of 2-methyl-6-trifluoromethoxyindole by 3-bromoanisole to give 1-(3-methoxyphenyl)-2-methyl-6- trifluoromethoxyindole, followed by ether cleavage, followed by substitution at the 3-position with 4-methoxybenzoyl chloride, followed by ether formation with (S)-Et lactate and finally base hydrolysis of the ester functionality.

IT 668455-69-4P 668456-50-6P 668456-51-7P
668456-52-8P 668456-53-9P 668456-54-0P
668456-55-1P 668456-56-2P 668456-57-3P
668456-62-0P 668456-64-2P 668456-65-3P
668456-66-4P 668456-67-5P 668456-68-6P
668456-69-7P 668456-70-0P 668456-71-1P
668456-72-2P 668456-73-3P 668456-74-4P
668456-75-5P 668456-76-6P 668456-77-7P
668456-78-8P 668456-79-9P 668456-80-2P
668456-81-3P 668456-82-4P 668456-83-5P
668456-84-6P 668456-85-7P 668456-86-8P
668456-87-9P 668456-88-0P 668456-89-1P
668456-90-4P 668456-91-5P 668456-92-6P
668458-59-1P 668458-60-4P 668458-61-5P
668458-62-6P 668458-63-7P 668458-64-8P
668458-65-9P 668458-66-0P 668458-67-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of indoles having aryloxyalkanoic or arylalkanoic acid substituents as PPARγ agonists or partial agonists having anti-diabetic activity)

RN 668455-69-4 CAPLUS
CN Propanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-50-6 CAPLUS
CN Propanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-51-7 CAPLUS
CN Propanoic acid, 2-[3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-52-8 CAPLUS
CN Propanoic acid, 2-[3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-53-9 CAPLUS
CN Propanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-

(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-54-0 CAPLUS
CN Propanoic acid, 2-[3-[[3-(7-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-55-1 CAPLUS
CN Propanoic acid, 2-[3-[[3-(7-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-56-2 CAPLUS
CN Propanoic acid, 2-[2-chloro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-57-3 CAPLUS
CN Propanoic acid, 2-[2-chloro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-62-0 CAPLUS
CN Butanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-64-2 CAPLUS
CN Butanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-65-3 CAPLUS
CN Butanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-66-4 CAPLUS
CN Propanoic acid, 2-[4-chloro-3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-67-5 CAPLUS
CN Propanoic acid, 2-[2-chloro-5-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-68-6 CAPLUS
CN Propanoic acid, 2-[4-chloro-3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-69-7 CAPLUS
CN Butanoic acid, 2-[3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-70-0 CAPLUS
CN Butanoic acid, 2-[3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-71-1 CAPLUS
CN Propanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-72-2 CAPLUS
CN Propanoic acid, 2-[3-[[3-(5-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-73-3 CAPLUS
CN Propanoic acid, 2-[3-[[3-(5-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-74-4 CAPLUS
CN Butanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-75-5 CAPLUS
CN Butanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-

methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-76-6 CAPLUS
CN Pentanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 668456-77-7 CAPLUS
CN Butanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-3-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-78-8 CAPLUS
CN Propanoic acid, 2-[2-chloro-5-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-79-9 CAPLUS
CN Butanoic acid, 2-[4-chloro-3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-80-2 CAPLUS
CN Butanoic acid, 2-[4-chloro-3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-81-3 CAPLUS
CN Propanoic acid, 2-[5-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]-2-fluorophenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-82-4 CAPLUS
CN Propanoic acid, 2-[5-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]-2-fluorophenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-83-5 CAPLUS
CN Propanoic acid, 2-[3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]-4-fluorophenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-84-6 CAPLUS
CN Propanoic acid, 2-[3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]-4-fluorophenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-85-7 CAPLUS
CN Propanoic acid, 2-[2-fluoro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-86-8 CAPLUS
CN Propanoic acid, 2-[2-fluoro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-87-9 CAPLUS
CN Propanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 668456-88-0 CAPLUS
CN Propanoic acid, 2-[4-fluoro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-89-1 CAPLUS
CN Propanoic acid, 2-[4-fluoro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668456-90-4 CAPLUS
CN Pentanoic acid, 2-[2-chloro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]- (9CI) (CA

INDEX NAME)



RN 668456-91-5 CAPLUS
CN Pentanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 668456-92-6 CAPLUS
CN Butanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-3-methyl- (9CI) (CA INDEX NAME)



RN 668458-59-1 CAPLUS
CN Propanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668458-60-4 CAPLUS
CN Propanoic acid, 2-[3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668458-61-5 CAPLUS
CN Propanoic acid, 2-[3-[[3-(6-chloro-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668458-62-6 CAPLUS
CN Propanoic acid, 2-[3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668458-63-7 CAPLUS
CN Propanoic acid, 2-[3-[[3-(7-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668458-64-8 CAPLUS
CN Propanoic acid, 2-[3-[[3-(7-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668458-65-9 CAPLUS
CN Propanoic acid, 2-[2-chloro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668458-66-0 CAPLUS
CN Propanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668458-67-1 CAPLUS
CN Propanoic acid, 2-[2-chloro-5-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, sodium salt, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 668455-75-2P 668455-77-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indoles having aryloxyalkanoic or arylalkanoic acid substituents as PPARγ agonists or partial agonists having anti-diabetic activity)

RN 668455-75-2 CAPLUS
CN 1H-Indole, 3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-1-[(4-methylphenyl)sulfonyl]-6-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 668455-77-4 CAPLUS
CN Propanoic acid, 2-[4-chloro-3-[[3-(6-methoxy-1,2-benzisoxazol-3-yl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl]phenoxy]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 . THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 06:46:48 ON 01 OCT 2007)

FILE 'REGISTRY' ENTERED AT 06:46:55 ON 01 OCT 2007
L1 1776331 S NC4/ESS (S) C6/ESS
L2 37784 S NOC3/ESS (S) C6/ESS
L3 STRUCTURE UPLOADED
L4 2143 S L1 AND L2
L5 10 S L3 SAM SUB=L4
L6 117 S L3 SSS FULL SUB=L4

FILE 'CAPLUS' ENTERED AT 06:48:09 ON 01 OCT 2007
L7 6 S L6
L8 1 S US2001-525470/APPS
L9 5 S L7 NOT L8

FILE 'REGISTRY' ENTERED AT 06:48:32 ON 01 OCT 2007

FILE 'CAPLUS' ENTERED AT 06:48:53 ON 01 OCT 2007

=> sav tem l6 brd525470/a
ANSWER SET NOT SAVED.
THE ANSWER SET WAS CREATED IN FILE 'REGISTRY'.
USE THE FILE COMMAND TO CHANGE TO THE CORRECT FILE.
Answer sets must be saved in the same file in which they were created.

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.12	227.62
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.68	-4.68

FILE 'REGISTRY' ENTERED AT 06:50:00 ON 01 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 SEP 2007 HIGHEST RN 948879-65-0
DICTIONARY FILE UPDATES: 30 SEP 2007 HIGHEST RN 948879-65-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d his

(FILE 'HOME' ENTERED AT 06:46:48 ON 01 OCT 2007)

FILE 'REGISTRY' ENTERED AT 06:46:55 ON 01 OCT 2007
L1 1776331 S NC4/ESS (S) C6/ESS
L2 37784 S NOC3/ESS (S) C6/ESS
L3 STRUCTURE UPLOADED
L4 2143 S L1 AND L2
L5 10 S L3 SAM SUB=L4
L6 117 S L3 SSS FULL SUB=L4

FILE 'CAPLUS' ENTERED AT 06:48:09 ON 01 OCT 2007
L7 6 S L6
L8 1 S US2001-525470/APPS
L9 5 S L7 NOT L8

FILE 'REGISTRY' ENTERED AT 06:48:32 ON 01 OCT 2007

FILE 'CAPLUS' ENTERED AT 06:48:53 ON 01 OCT 2007

FILE 'REGISTRY' ENTERED AT 06:50:00 ON 01 OCT 2007

=> sav tem l6 brd525470/a

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.45	228.07
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.68

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 06:50:14 ON 01 OCT 2007